Inimmune Corporation Profile last edited on: 10/8/2020
CAGE: 7U1Q8
UEI: EF8AMXMGG8W5
Business Identifier: Novel immunotherapeutics 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
1121 East Broadway Street Unit 121
Missoula, MT 59802
Missoula, MT 59802
| (406) 360-2732 |
| info@inimmune.com |
| www.inimmune.com |
Location: Single
Congr. District: 01
County: Missoula
Congr. District: 01
County: Missoula
Public Profile
With several of the firm's personnel formerly with a major pharmaeutical firm (GSK) that was consolidating its operation in the State of Montana, in close collaboration with the University of Montana, Inimmune was formed, The firm is organized around harnessing the human immune system to create next generation of new immunomodulatory therapeutics for the treatment or prevention of allergy, autoimmunity, upper respiratoty tract infections and cancer, by targeting innate immune receptors. Members of the assembled team collectively have decades of relevant expertise discovering and developing safe and effective immunomodulators that can be used for the treatment of a wide array of diseases and disorders.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
25-49Revenue Range
2.5M-5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2021 | 2 | NIH | $1,836,454 | |
| Project Title: The Goal of This Research Program Is to Develop a Self-Administered Intranasal Tlr4 Agonist to Treat Allergic Rhinitis. Unlikeantigen-Specific Therapy | ||||
| 2020 | 2 | NIH | $1,992,472 | |
| Project Title: Production of Synthetic Adjuvant System (SAS) | ||||
| 2020 | 2 | NIH | $1,194,124 | |
| Project Title: Novel Synthetic TLR4 Agonists | ||||
| 2018 | 1 | NIH | $592,624 | |
| Project Title: Discovery of new small molecule TLR4 agonists for the treatment of allergic rhinitis | ||||
Key People / Management
Jay T Evans -- Founder, President and Chief Executive Officer
Helene Bazin-Lee -- Founder and Vice President, Early Discovery
David J Burkhart -- Founder and Chief Operating Officer
Juhienah Khalaf
Shannon Miller
Kendal Ryter -- Vice President, Manufacturing and Dev
Alyson Smith -- Director of Immunology
Helene Bazin-Lee -- Founder and Vice President, Early Discovery
David J Burkhart -- Founder and Chief Operating Officer
Juhienah Khalaf
Shannon Miller
Kendal Ryter -- Vice President, Manufacturing and Dev
Alyson Smith -- Director of Immunology
Company News
|
Nov
01
2016
|
New Biotech Company Formed at UM's MonTEC |
